Lexicon Pharmaceuticals : LXRX

All Lexicon Pharmaceuticals Articles

38 Articles

Lee Jackson | Oct 3, 2017 at 9:45 AM EDT

Wedbush Makes Big Changes to Best Ideas List for October

These top picks from Wedbush offer varying degrees of risk and upside. The fact that they are not crowded momentum…

Paul Ausick | Sep 14, 2017 at 4:04 PM EDT

Equifax, New York REIT Dive into Thursday’s 52-Week Low Club

Equifax, New York REIT, Opko, and Lexicon Pharma all posted new 52-week lows Thursday.

Paul Ausick | Sep 13, 2017 at 4:04 PM EDT

Equifax, HP Enterprise Tumble into Wednesday’s 52-Week Low Club

Hewlett Packard Enterprise, Equifax, New York REIT, and Lexicon Pharmaceuticals all posted new 52-week lows on Wednesday.

Jon C. Ogg | Jun 12, 2017 at 9:06 AM EDT

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

The top analyst upgrades, downgrades and other research calls from Monday Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna and Lexicon Pharma.

Chris Lange | Jun 9, 2017 at 8:45 AM EDT

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Shares of Lexicon Pharmaceuticals saw a hand gain early on Friday after the company reported top-line results from its late-stage…

Lee Jackson | Mar 3, 2017 at 9:55 AM EST

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Here are three biotech companies that not only have data that could prove to be huge, but their shares have…

Lee Jackson | Mar 1, 2017 at 9:15 AM EST

Top Analysts Upgrades and Downgrades: Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks, Salesforce and More

Wednesday’s top analyst upgrades, downgrades and initiations include Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks and…

Chris Lange | Jan 31, 2017 at 7:35 AM EST

Wedbush’s 6 Best Idea Stocks for 50% Upside (or Much More)

Wedbush has issued a report with some of its best ideas for 2016. These top six ideas from this list…

Chris Lange | Jan 6, 2017 at 10:25 AM EST

6 Major FDA Decisions and Biopharma Catalysts Coming in January and February

Some biopharma companies can see a massive upside just from winning a single mid-stage trial or even achieving as much…

Chris Lange | Dec 30, 2016 at 7:45 AM EST

7 Key FDA Decisions and Catalysts Expected in January and February

24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two…

Chris Lange | Dec 5, 2016 at 1:05 PM EST

10 Major Pharma and FDA Catalysts Coming in December

24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.

Chris Lange | Sep 11, 2016 at 10:35 AM EDT

4 Key BioPharma Movers in the Past Week

Some biotech companies made impressive runs over the course of this past week. These select few stood out from the…

Chris Lange | Sep 9, 2016 at 9:45 AM EDT

Why Lexicon Pharma Is Soaring

Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.

Chris Lange | Sep 5, 2015 at 9:05 AM EDT

4 New Big FDA Decisions Expected in September

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and…

Jon C. Ogg | Mar 14, 2015 at 9:20 AM EDT

8 Analyst Stocks Under $10 With Massive Upside Calls

This past week was a break from the endless, six-year bull market. Still, the market remains effectively at all-time highs.

1 2 3

Lexicon Pharmaceuticals : LXRX

All Lexicon Pharmaceuticals Articles

Wedbush Makes Big Changes to Best Ideas List for October

Equifax, New York REIT Dive into Thursday’s 52-Week Low Club

Equifax, HP Enterprise Tumble into Wednesday’s 52-Week Low Club

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Top Analysts Upgrades and Downgrades: Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks, Salesforce and More

Wedbush’s 6 Best Idea Stocks for 50% Upside (or Much More)

6 Major FDA Decisions and Biopharma Catalysts Coming in January and February

7 Key FDA Decisions and Catalysts Expected in January and February

10 Major Pharma and FDA Catalysts Coming in December

4 Key BioPharma Movers in the Past Week

Why Lexicon Pharma Is Soaring

4 New Big FDA Decisions Expected in September

8 Analyst Stocks Under $10 With Massive Upside Calls

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lexicon Pharmaceuticals : LXRX

All Lexicon Pharmaceuticals Articles

Wedbush Makes Big Changes to Best Ideas List for October

Equifax, New York REIT Dive into Thursday’s 52-Week Low Club

Equifax, HP Enterprise Tumble into Wednesday’s 52-Week Low Club

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

Lexicon Pharmaceuticals Rises on Late-Stage Diabetes Trial

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Top Analysts Upgrades and Downgrades: Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks, Salesforce and More

Wedbush’s 6 Best Idea Stocks for 50% Upside (or Much More)

6 Major FDA Decisions and Biopharma Catalysts Coming in January and February

7 Key FDA Decisions and Catalysts Expected in January and February

10 Major Pharma and FDA Catalysts Coming in December

4 Key BioPharma Movers in the Past Week

Why Lexicon Pharma Is Soaring

4 New Big FDA Decisions Expected in September

8 Analyst Stocks Under $10 With Massive Upside Calls

Silver and Copper Are Outpacing Gold in 2026 and After Following Industrial Metals These 3 ETFs Show How Smart Money Is Playing the Trend

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check

Featured Reads

At 65, Your HSA Stops Being a Medical Account and Starts Beating Your 401(k)

Lower Your Mortgage Payment Without Refinancing, Without Closing Costs, and Without a Credit Check